Envestnet Asset Management
FSTX

Envestnet Asset Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Envestnet Asset Management’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,067
Closed -$69.9K – 4168
2022
Q4 		$69.9K Sell
11,067
-1,335
-11% -$7.39K ﹤0.01% 3847
2022
Q3 		$63K Sell
12,402
-1,911
-13% -$12K ﹤0.01% 3792
2022
Q2 		$90K Buy
14,313
+749
+6% +$2.52K ﹤0.01% 3766
2022
Q1 		$48K Buy
+13,564
New +$50.1K ﹤0.01% 3863

Envestnet Asset Management's FSTX Position: Q1 2023 in Review

Envestnet Asset Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 11,067 shares — an estimated $69.9K sold.

Envestnet Asset Management first reported a position in FSTX in Q1 2022 and held it in 4 quarters. The position peaked at $90K in Q2 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • Envestnet Asset Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 11,067 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $69.9K.
  • Envestnet Asset Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Envestnet Asset Management's F-star Therapeutics, Inc. Common Stock position peaked at $90K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Envestnet Asset Management's 13F filing for Q1 2023, filed 11 May 2023.